- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05732961
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
A Phase 2, Single Arm Study of Luspatercept for the Treatment of Anemia in Lower Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Myelodysplastic Syndromes/ Myeloproliferative Neoplasms (MDS/MPN)
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Rami Komrokji, MD
- Phone Number: 813-745-4748
- Email: Rami.Komrokji@moffitt.org
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
Contact:
- Lisa Nardelli
- Phone Number: 813-745-4731
- Email: Lisa.Nardelli@moffitt.org
-
Principal Investigator:
- Rami Komrokji, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant is ≥18 years at the time of signing the informed consent form
- Participant is willing and able to adhere to the study visit schedule and other protocol requirements
Documented diagnosis of MDS or non-proliferative MDS/MPN (WBC < 13,000 U/L)
- According to WHO 2016 classification
- Meets IPSS-R classification of very low, low, or intermediate risk disease
Documented acquired splicing gene mutation
- Cohort 1: detectable splicing mutation other than SF3B1: (SRSF2, U2AF1, ZRSR2)
- Cohort 2: SF3B1 mutation with prior treatment with hypomethylating agent and or lenalidomide
- <5% blasts in bone marrow
Refractory, intolerant to, or ineligible for, prior ESA treatment, as defined by any one of the following:
Refractory to prior ESA treatment - non-response or response that is no longer maintained. ESA regimen must have been either:
- rHu EPO ≥ 40,000 IU/wk for at least 8 doses or equivalent Or darbepoetin alpha ≥ 500 μg Q3W for at least 4 doses or equivalent
- Intolerant to prior ESA treatment - discontinuation of prior ESA-containing regimen, at any time after introduction due to intolerance or AE
- ESA ineligible - Low chance of response to ESA based on endogenous serum EPO > 200 U/L for subjects not previously treated with ESAs
- Discontinuation of ESAs, G-CSF, GM-CSF ≥ 4 weeks prior to start of study treatment
Require RBC transfusions
a. Average of ≥ 2 units/8 weeks of pRBCs confirmed for a minimum of 16 weeks immediately preceding registration
Applies to on treatment subjects only - females of childbearing potential (FCBP) defined as a sexually mature woman who:
- has achieved menarche at some point,
- has not undergone a hysterectomy or bilateral oophorectomy, or
has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months) and must:
- Have two negative pregnancy tests 48 hours apart as verified by the investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study therapy. This applies even if the subject practices true abstinence* from heterosexual contact.
- Either commit to true abstinence*from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with highly effective, contraception without interruption, 35 days prior to starting
- investigational product (IP), during the study therapy (including dose interruptions), and for 84 days after discontinuation of study therapy
Applies to on treatment subjects only - Male subjects must:
- Practice true abstinence* (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 84 days following investigational product discontinuation even if he has undergone a successful vasectomy. * True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception).
Exclusion Criteria:
- Prior allogeneic or autologous stem cell transplant
- MDS associated with del 5q cytogenetic abnormality if no prior lenalidomide treatment
- Uncontrolled hypertension, defined as repeated elevations of diastolic blood pressure (DBP) ≥ 100 mmHg despite adequate treatment
- ANC < 500/μL (0.5 x 109/L)
- Platelet count ˂50,000/μL (50 x 109/L)
- Active other malignancies
- Severe renal impairment (eGFR < 30 mL/min/1.73 m2)
- ALT or AST ≥ 3 × ULN
- Prior treatment with Luspatercept or Sotatercept
- Pregnant or breastfeeding females
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Participants with gene mutations other than SF3B1
Participants with lower risk MDS or non-proliferative MDS/MPN with somatic splicing gene mutations other than SF3B1
|
Participants will be treated with Luspatercept, with a starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
Other Names:
|
Experimental: Participants with SF3B1 mutation
Participants with lower risk MDS or non-proliferative MDS/MPN with SF3B1 mutation who had received hypomethylating agents and or lenalidomide.
|
Participants will be treated with Luspatercept, with a starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
RBC Transfusion Independence
Time Frame: From start of treatment to up to 18 months
|
RBC transfusion independence (RBC-TI) as defined by IWG 2006 MDS response criteria
|
From start of treatment to up to 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment related adverse events
Time Frame: From start of treatment to 30 days after the last day of treatment, up to 19 months
|
To determine the number of participants with treatment related AEs using CTCAE v5
|
From start of treatment to 30 days after the last day of treatment, up to 19 months
|
Hematological Improvement
Time Frame: From start of treatment to up to 18 months
|
Hematological improvement as defined by using IWG 2006 MDS response criteria
|
From start of treatment to up to 18 months
|
Duration of Response
Time Frame: From start of treatment to up to 18 months
|
The duration of response is measured from the time measurement criteria are met for RBC TI or HI by IWG 2006 criteria until the first date of loss of response or progressive disease is objectively documented.
|
From start of treatment to up to 18 months
|
ASC specks changes with response
Time Frame: End of treatment, up to 18 months
|
ASC specks as biomarker of response, investigators will compare mean baseline percentage of ASC specks among responders and non-responders (t-test) and use paired t-test to compare change in mean percentage of ASC specks with treatment among responders and non-responders
|
End of treatment, up to 18 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Rami Komrokji, MD, Moffitt Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MCC-21405
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndromes
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
National Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
GCP-Service International West GmbHSaint-Louis Hospital, Paris, France; University of Florence; Medical University... and other collaboratorsNot yet recruitingLow Risk Myelodysplastic SyndromesSpain, Poland, Italy, Germany, France
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes (MDS)United States
-
TJ Biopharma Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
-
Sumitomo Pharma America, Inc.TerminatedMyelodysplastic Syndromes (MDS)United States
Clinical Trials on Luspatercept
-
University of LeipzigCelgene CorporationRecruitingMyelodysplastic Syndromes | AnemiaGermany
-
Associazione Qol-oneRecruitingMyelodysplastic Syndromes | Anemia | Transfusion-dependent Anemia | Del(5Q)Italy
-
Acceleron Pharma Inc. (a wholly owned subsidiary...Completed
-
Acceleron Pharma Inc. (a wholly owned subsidiary...Completed
-
Acceleron Pharma Inc. (a wholly owned subsidiary...Completed
-
Acceleron Pharma Inc. (a wholly owned subsidiary...CompletedB-ThalassemiaItaly, Greece
-
Sun Yat-sen UniversityRecruitingThalassemia Major | Transfusion-dependent AnemiaChina
-
Groupe Francophone des MyelodysplasiesCelgeneRecruitingMyelodysplastic Syndromes | MDSFrance
-
Hematology department of the 920th hospitalRecruiting
-
Bristol-Myers SquibbRecruitingMyelodysplastic Syndrome | Beta ThalassemiaKorea, Republic of